Literature DB >> 19929377

Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers.

Sébastien Briolant1, Nathalie Wurtz, Agnès Zettor, Christophe Rogier, Bruno Pradines.   

Abstract

BACKGROUND: Doxycycline is used in combination with quinine for malaria treatment or alone for malaria chemoprophylaxis. However, the occurrence of malaria after doxycycline chemoprophylaxis has been reported. Identification of genetic determinants that contribute to the susceptibility of Plasmodium falciparum to doxycycline will be important for the detection and surveillance of doxycycline resistance.
METHODS: Sequence analysis of 11 genes (pftufA, pfEF-TS, pfmdt, pftetQ, pfrps3, pfrps7, pfrps8, pfrps9, pfrps11, pfrps14, and pfrps17) and evaluation of pfmdt and pftetQ copy numbers by quantitative real-time polymerase chain reaction were conducted in 90 African P. falciparum isolates that were obtained from 14 countries and that belonged to phenotypic groups differing in their doxycycline median inhibitory concentrations.
RESULTS: We found that pfmdt copy number of >1 (adjusted odds ratio [OR], 7.09 [95% confidence interval {CI}, 1.58-31.82]; P=.011), pftetQ copy number of >1 (adjusted OR, 5.23 [95% CI, 1.06-25.77]; P=.042), and KYNNNN amino acid motif repeats of <3 (adjusted OR, 3.00 [95% CI, 1.02-8.86]; P=.046) were independently associated with decreased susceptibility to doxycycline.
CONCLUSIONS: Our findings suggest that pfmdt and pftetQ copy numbers and pftetQ sequence polymorphisms are potential molecular markers of decreased in vitro susceptibility to doxycycline in African P. falciparum isolates.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19929377     DOI: 10.1086/648594

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Delayed Onset of Plasmodium falciparum Malaria after Doxycycline Prophylaxis in a Soldier Returning from the Central African Republic.

Authors:  Emilie Javelle; Marylin Madamet; Tiphaine Gaillard; Guillaume Velut; Corinne Surcouf; Rémy Michel; Eric Garnotel; Fabrice Simon; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites.

Authors:  Richard T Eastman; Neekesh V Dharia; Elizabeth A Winzeler; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

3.  Molecular Markers and In Vitro Susceptibility to Doxycycline in Plasmodium falciparum Isolates from Thailand.

Authors:  Tiphaine Gaillard; Kanlaya Sriprawat; Sébastien Briolant; Chirapat Wangsing; Nathalie Wurtz; Meïli Baragatti; Morgane Lavina; Aurélie Pascual; François Nosten; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

4.  Absence of association between piperaquine in vitro responses and polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe genes in Plasmodium falciparum.

Authors:  Sébastien Briolant; Maud Henry; Claude Oeuvray; Rémy Amalvict; Eric Baret; Eric Didillon; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Plasmodium falciparum proteome changes in response to doxycycline treatment.

Authors:  Sébastien Briolant; Lionel Almeras; Maya Belghazi; Elodie Boucomont-Chapeaublanc; Nathalie Wurtz; Albin Fontaine; Samuel Granjeaud; Thierry Fusaï; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

Review 6.  The interplay between drug resistance and fitness in malaria parasites.

Authors:  Philip J Rosenthal
Journal:  Mol Microbiol       Date:  2013-08-16       Impact factor: 3.501

7.  Reduced in vitro doxycycline susceptibility in plasmodium falciparum field isolates from Kenya is associated with PfTetQ KYNNNN sequence polymorphism.

Authors:  Angela O Achieng; Luiser A Ingasia; Dennis W Juma; Agnes C Cheruiyot; Charles A Okudo; Redemptah A Yeda; Jelagat Cheruiyot; Hoseah M Akala; Jacob Johnson; Ben Andangalu; Fredrick Eyase; Walter G Z O Jura; Edwin Kamau
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

8.  Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast.

Authors:  Nathalie Wurtz; Aurélie Pascual; Adeline Marin-Jauffre; Housem Bouchiba; Nicolas Benoit; Marc Desbordes; Maryse Martelloni; Vincent Pommier de Santi; Georges Richa; Nicolas Taudon; Bruno Pradines; Sébastien Briolant
Journal:  Malar J       Date:  2012-05-02       Impact factor: 2.979

9.  Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis.

Authors:  Kathrine R Tan; Alan J Magill; Monica E Parise; Paul M Arguin
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

10.  Trafficked Proteins-Druggable in Plasmodium falciparum?

Authors:  Jasmin Lindner; Kamila Anna Meissner; Isolmar Schettert; Carsten Wrenger
Journal:  Int J Cell Biol       Date:  2013-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.